Lokhorst HM - Search Results

1

VAD chemotherapy for refractory multiple myeloma.

Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW. Lokhorst HM, et al. Br J Haematol. 1989 Jan;71(1):25-30. doi: 10.1111/j.1365-2141.1989.tb06269.x. Br J Haematol. 1989. PMID: 2644970

2

High-risk multiple myeloma treated with high-dose melphalan.

Lokhorst HM, Meuwissen OJ, Verdonck LF, Dekker AW. Lokhorst HM, et al. J Clin Oncol. 1992 Jan;10(1):47-51. doi: 10.1200/JCO.1992.10.1.47. J Clin Oncol. 1992. PMID: 1727925

3

J chain disease: an aggressive evolution of multiple myeloma.

Lokhorst HM, Dekker AW, Baarlen JV, Bast EJ. Lokhorst HM, et al. Am J Med. 1990 Apr;88(4):417-20. doi: 10.1016/0002-9343(90)90500-d. Am J Med. 1990. PMID: 2109533 No abstract available.

4

Advances in the treatment of multiple myeloma.

Lokhorst HM, Dekker AW. Lokhorst HM, et al. Cancer Treat Rev. 1993 Apr;19(2):113-28. doi: 10.1016/0305-7372(93)90030-u. Cancer Treat Rev. 1993. PMID: 7683253 Review. No abstract available.

5

MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.

Cornelissen JJ, Sonneveld P, Schoester M, Raaijmakers HG, Nieuwenhuis HK, Dekker AW, Lokhorst HM. Cornelissen JJ, et al. Among authors: lokhorst hm. J Clin Oncol. 1994 Jan;12(1):115-9. doi: 10.1200/JCO.1994.12.1.115. J Clin Oncol. 1994. PMID: 7903690

6

Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma.

Lokhorst HM, Sonneveld P, Wijermans PW, van Marwijk Kooy M, Meuwissen OJ, van Oers RH, van der Griend R, Dekker AW. Lokhorst HM, et al. Br J Haematol. 1996 Jan;92(1):44-8. doi: 10.1046/j.1365-2141.1996.00306.x. Br J Haematol. 1996. PMID: 8562409 Clinical Trial.

7

Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.

Raaijmakers HG, Izquierdo MA, Lokhorst HM, de Leeuw C, Belien JA, Bloem AC, Dekker AW, Scheper RJ, Sonneveld P. Raaijmakers HG, et al. Among authors: lokhorst hm. Blood. 1998 Feb 1;91(3):1029-36. Blood. 1998. PMID: 9446666 Free article.

8

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.

Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM. Segeren CM, et al. Among authors: lokhorst hm. Br J Haematol. 1999 Apr;105(1):127-30. Br J Haematol. 1999. PMID: 10233375 Free article. Clinical Trial.

9

Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma.

Terpstra WE, Lokhorst HM, Blomjous F, Meuwissen OJ, Dekker AW. Terpstra WE, et al. Among authors: lokhorst hm. Br J Haematol. 1992 Sep;82(1):46-9. doi: 10.1111/j.1365-2141.1992.tb04592.x. Br J Haematol. 1992. PMID: 1419801

10

Graft-versus-myeloma effect in two cases.

Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Verdonck LF, et al. Among authors: lokhorst hm. Lancet. 1996 Mar 23;347(9004):800-1. doi: 10.1016/s0140-6736(96)90871-5. Lancet. 1996. PMID: 8622337

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters